Latest news with #RoyalDevonUniversityHealthcare
Yahoo
10-07-2025
- Health
- Yahoo
New 'groundbreaking' diabetes treatment trialled by NHS could delay insulin need
A revolutionary medication designed to slow the progression of type 1 diabetes is currently being tested by a small number of NHS patients across the UK. Teplizumab, which has already received approval in the United States, teaches the immune system to cease its assault on pancreatic cells, postponing the requirement for insulin by an average of three years. In type 1 diabetes, the body's immune system launches an attack on the insulin-producing cells within the pancreas, resulting in the loss of natural blood sugar regulation. When blood glucose levels become excessively high or dangerously low, it can lead to severe health complications and potentially prove fatal. Individuals diagnosed with type 1 diabetes consequently require daily insulin injections. READ MORE: NHS says 'contact your GP practice' if you notice symptom that 'could be cancer' READ MORE: Preeclampsia may reduce lifelong risk of multiple cancers up to 45%, new study finds Hannah Robinson, a 36-year-old dentist and mother of two from Devon, has become the first adult in the UK to trial the medication in hopes of delaying the onset of her condition. She is receiving care at the Royal Devon University Healthcare NHS Foundation Trust following the discovery during her pregnancy that she was in the preliminary stages of developing type 1 diabetes. A small group of individuals are receiving the treatment on an individual assessment basis whilst it undergoes evaluation for broader NHS implementation. She explained: "For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. "This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. "This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this." Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: "This new treatment represents a really exciting shift in how we manage type 1 diabetes. "For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. "Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. "My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all." Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: "For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. "Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. "That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. "Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes." Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, commented: "Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. "It is really important to find new and improved approaches for identifying individuals at elevated risk."
The Independent
08-07-2025
- Health
- The Independent
‘Groundbreaking' drug could slow progression of type 1 diabetes
A 'groundbreaking' drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK. Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
The Independent
08-07-2025
- Health
- The Independent
Drug breakthrough for patients with type 1 diabetes
A new drug, teplizumab, offers hope for delaying the need for insulin in people with type 1 diabetes by an average of three years. Hannah Robinson, a 36-year-old dentist, is the first adult in the UK to receive teplizumab, administered at Royal Devon University Healthcare NHS Foundation Trust. The drug works by training the immune system to stop attacking insulin-producing cells in the pancreas, but it must be given at the earliest stage of the disease to be effective. Teplizumab is already approved in the US and is currently being reviewed for wider use on the NHS in the UK, with a few other patients receiving it on a case-by-case basis. Experts are working on establishing national screening programmes to identify individuals at high risk of type 1 diabetes early, aiming to make this treatment widely available and potentially prevent the need for insulin altogether.
Yahoo
08-07-2025
- Health
- Yahoo
‘Groundbreaking' drug could slow down progression of type 1 diabetes
A 'groundbreaking' drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK. Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
The Independent
07-07-2025
- Health
- The Independent
Mother of two becomes the first UK patient to receive ‘groundbreaking' new diabetes drug
A mother of two has become the first adult in the UK to try a 'groundbreaking' drug which can delay the need for insulin in diabetes patients. Hannah Robinson, a 36-year-old dentist, is being treated with teplizumab at Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1 diabetes. A handful of people are also being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. With type 1 diabetes, the immune system attacks insulin -producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body and people with the condition, therefore, need daily insulin. If blood sugar is too high or too low, it can cause serious health problems and even death. Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average three years. Ms Robinson said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' Teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is that more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.'
